These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 30692121)
1. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Martin P; Bartlett NL; Blum KA; Park S; Maddocks K; Ruan J; Ridling L; Dittus C; Chen Z; Huang X; Inghirami G; DiLiberto M; Chen-Kiang S; Leonard JP Blood; 2019 Mar; 133(11):1201-1204. PubMed ID: 30692121 [TBL] [Abstract][Full Text] [Related]
2. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Martin P; Ruan J; Furman R; Rutherford S; Allan J; Chen Z; Huang X; DiLiberto M; Chen-Kiang S; Leonard JP Leuk Lymphoma; 2019 Dec; 60(12):2917-2921. PubMed ID: 31120355 [TBL] [Abstract][Full Text] [Related]
3. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091 [TBL] [Abstract][Full Text] [Related]
4. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR; Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987 [TBL] [Abstract][Full Text] [Related]
5. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202 [TBL] [Abstract][Full Text] [Related]
6. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088 [TBL] [Abstract][Full Text] [Related]
7. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547 [TBL] [Abstract][Full Text] [Related]
8. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039 [TBL] [Abstract][Full Text] [Related]
9. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M; Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234 [TBL] [Abstract][Full Text] [Related]
11. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553 [TBL] [Abstract][Full Text] [Related]
13. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157 [TBL] [Abstract][Full Text] [Related]
14. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229 [TBL] [Abstract][Full Text] [Related]
15. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723 [TBL] [Abstract][Full Text] [Related]
16. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811 [TBL] [Abstract][Full Text] [Related]